Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

Part of paid clinical trials in Fleming Island, Florida.

Sponsor
Bristol-Myers Squibb
Study ID
NCT07215962
Status
Active Not Recruiting

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to assess the treatment-related adverse events and associated healthcare resource use in programmed death ligand 1 (PD-L1) negative individuals diagnosed with advanced/metastatic non-small cell lung cancer (NSCLC) who received first-line therapy

Key Dates

First listed
Oct 14, 2025
Start date
Nov 22, 2024
Status verified
Oct 2025
Primary completion
Jul 1, 2025
Completion
Mar 1, 2026

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Cohort 1
    Participants receiving nivolumab + ipilimumab treatment
  • Arm: Cohort 2
    Participants receiving nivolumab + ipilimumab + platinum-based chemotherapy
  • Arm: Cohort 3
    Participants receiving immuno-oncology therapy (excl nivolumab) with chemotherapy treatment
  • Arm: Cohort 4
    Participants receiving other dual-IO with chemotherapy

Primary Outcome Measure

Incidence of treatment-related adverse events [ Time Frame: Baseline ]

Locations (1)

FacilityCityStateZIPSite coordinators
Florida Cancer Specialists & Research InstituteFleming IslandFlorida32003-

Find similar trials in Fleming Island, FL

By research site
Florida Cancer Specialists & Research Institute· Fleming Island, FL

Related Studies